TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Patient's global evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perception of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: satisfactory birth experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive predictive value of PSA screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of biopsies necessary to detect 1 case of PCa
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: time to angina during exercise testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total number of episodes of chest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of new chronic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of developing 1+ new chronic disease(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hazard ratio for developing 3+ new chronic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall closure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mean closure time per centimeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: intersurgeon and interpatient variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of adhesive ileus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recovery of gut motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postoperative abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bond strength of fissure sealant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean loss of vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients losing at least 3 lines of vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in disruptive behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum high sensitivity C-reactive protein (hs-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of return of spontaneous circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Alive at hospital discharge
Endpoint domain: Mortality/survival
Primary endpoint: Number of required PDT retreatments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PSP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of maternal hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Length of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Positive coping style
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Psychological self-help ability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Forward gait speed change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Backward gait speed change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Training time on the box trainer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: First attempts time on the box trainer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Objective success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective success rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in daily practice of NPIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: repeat operation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Self-evaluated symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Japanese Rhinoconjunctivitis Quality of Life Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occurrence of stroke
Endpoint domain: Adverse events/effects
Primary endpoint: plasma ferritin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 11β‐HSD2 enzyme activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: five-year progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in gingival index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DR progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DR regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of lost weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum potassium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recurrence of hyperkalemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: caesarean birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: postpartum haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: breastfeeding initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: adolescent depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence of oral dosage forms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of the intervention as intended
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: t lim improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite endpoint of stroke, systemic embolism, and major bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of tumour necrosis factor‐alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of plasminogen activator inhibitor‐1 antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of soluble intercellular adhesion molecule‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anal resting pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rockwood fecal incontinence score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of raised ICP to less than 20 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Influenza risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postvaccination HAI titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effectiveness in pain during activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness in pain at night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in pain at night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall satisfaction ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvements in standing to supine transition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in supine to standing transition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of bacteria in saliva samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Normalization of menstrual cyclicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of androgen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of tuberculosis (TB) cases
Endpoint domain: Adverse events/effects
Primary endpoint: anterior corneal aberrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Pcuff values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary calcium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum 1,25-dihydroxyvitamin D concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Strength gains for leg press
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength gains for leg extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new-onset diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: V˙O2 during steady-state exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse events (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality within four months after onset of pancreatitis
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of at least 1 AM
Endpoint domain: Adverse events/effects
Primary endpoint: Acquisition of cow's milk tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in child externalizing problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in child internalizing problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in parent problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Wheal size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Allergen-specific immunoglobulin E (IgE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of CD63, CD62P, PAI‐1 and C‐RP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time constant of oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Propofol blood clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Volume of distribution of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood elimination half-life of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: anterio‐posterior size of APA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical success rate at EOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiologic success rate at EOT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient/graft survival
Endpoint domain: Mortality/survival
Primary endpoint: Memory ability improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients receiving supplemental analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: EEG response changes (delta and alpha activity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Treatment adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PNES frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life in Epilepsy–10 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: QALY gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of intraperitoneal abscess
Endpoint domain: Adverse events/effects
Primary endpoint: Total symptom scores on nasal challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Titrated skin prick testing with cat dander extract
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cat-specific IgG4 measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bicarbonate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steady-state total exposure to ROF (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sore-throat symptoms in recovery
Endpoint domain: Adverse events/effects
Primary endpoint: First time to analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of pethidine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tooth yellowness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size reduction of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in Modified Overt Aggression Scale (MOAS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Problem Behaviour Check List scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stone expulsion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: expulsion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sleep induction success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for second sedative dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean serum 25-hydroxyvitamin D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful treatment of anemia (hemoglobin > 100 g/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient acceptance of contrast media
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Transit time of contrast media
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Homogeneous filling of the bowel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: EEG activity (alpha and theta)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Differential expression of protein spots
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in antibiotic dispensing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in fall-risk scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved postural stability (sway reduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: K(i) values based on unbound fluvoxamine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of rhegmatogenous retinal detachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year single procedure freedom from atrial arrhythmia off anti-arrhythmic drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident neck pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck flexion movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UUI episodes improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean voided volume (MVV) per micturition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Treatment response percentage
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ophthalmology global assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional limitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing time of autologous skin grafting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Basophil sensitivity to Ara h 2 stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: feasibility of indicators
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: anatomical success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual acuity recuperation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of myoclonus
Endpoint domain: Adverse events/effects
Primary endpoint: Subclinical respiratory depression
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of small-bowel polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Successful mobilization of CD34+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean number of days to achieve > 0.5 x 10(9) PMN/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean number of days to achieve > 20 x 10(9) PLT/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Defibrillation threshold energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nonthoracotomy lead implantation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: OCD symptom severity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliable improvement in OCD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant pre-post treatment changes in OCD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper limb function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADL performance improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mean FDV of the lumbar muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: temperature index of the lumbar skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dynamic leg strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Objective Opioid Withdrawal Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total sleeping time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deterioration of functional results after PPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma branched‐chain amino acids concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hepatic fat storage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sustained remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in glomerular filtration rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Free-running speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bearing resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Noise level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrafiltration volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum maltose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic activity (AUC0-8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking cessation
Endpoint domain: Mortality/survival
Primary endpoint: Varenicline adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of air leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioavailability of moxifloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to maximum concentration (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GH response to HEX administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes